2.2.1. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) systematic review on HIVST
Since 2014, WHO has encouraging countries to implement pilot HIVST programmes to evaluate this potential approach. In this 2016 guideline, WHO has issued a strong recommendation that HIVST should be offered as an additional approach to delivering HTS. The Guideline Development Group (GDG) has determined the evidence reviewed on HIVST to be of moderate quality.
Discussion of this recommendation follows, along with a summary of the results of two systematic reviews and a literature review of values and preferences of self-testers and potential self-testers, as well as providers and key stakeholders, on HIVST.
In accordance with the GRADE methodology, this review prioritized randomized controlled trials that directly compared HIVST to existing and standard HIV testing approaches (for example, facility-based or community-based HTS). Other studies, including trials and observational studies that reported outcomes of interest (such as uptake, positivity or linkage) but did not directly compare HIVST to standard HTS, were not included in the GRADE analysis and were summarized instead. Any study reporting on values and preferences, cost or cost-effectiveness related to HIVST was also summarized. See Annexes 16 and 17 for detailed information on the methodology and evidence from the systematic review.
The searches yielded 638 citations. After removing duplicate studies, reviewers considered 496 unique records and initially excluded 317 of these. After reviewing the remaining 179 records in full text, an additional 174 records were excluded because they did not meet the inclusion criteria. Ultimately, five randomized controlled trials were identified and included in the review. All five were conference abstracts, and additional study details were retrieved by directly contacting the authors.
The five randomized controlled trials (33–37) took place in four countries. All of them focused on reaching men. Two took place in Kenya, where women distributed HIVST kits to their male partners. This approach was compared with using letters or referral cards to invite their male partners for HIV testing at a clinic (35,36). The remaining studies were among men who have sex with men and took place in Australia (34), Hong Kong SAR of the People's Republic of China (37) and the United States of America (33); all of these studies compared the offer of HIVST with facility-based HTS.
All five randomized controlled trials offered free, oral fluid-based HIV RDTs for self-testing with the manufacturer's instructions for use, but they differed in terms of the number of kits available to participants and the level of assistance. In the United States, men who have sex with men had continuous access to HIVST kits; in Australia, participants had continuous access and received four HIVST kits at enrolment (34). In Kenya, women were provided with two HIVST kits at enrolment (one for themselves and one for their male partner) (35,36). In Hong Kong SAR, men who have sex with men were provided with only one HIVST kit at enrolment (37). Two randomized controlled trials provided unassisted HIVST: in addition to the test kit, participants were given a video link (34,37) and, in one of the trials, telephone-based motivational interviewing and social media-based pre- and post-test counselling (37). The other three randomized controlled trials provided direct assistance, including an in-person demonstration on how to self-test (33,35,36); in two of these trials, women were provided with the demonstration so they could show their male partners how to self-test (35,36).
Box 2.2Main outcomes of randomized control trials used in GRADE review
In general, the five randomized controlled trials concluded that, when compared to standard facility-based testing, HIV self-testing (HIVST):
Increased the uptake of HIV testing among male partners of pregnant or postpartum women and men who have sex with men.
Increased the uptake of couples HIV testing among male partners of pregnant or postpartum women.
Increased the frequency of HIV testing among men who have sex with men by approximately two times in a year.
Did not increase HIV risk behaviours (such as condomless anal intercourse) or the number of bacterial sexually transmitted infections (STIs).
Did not decrease the uptake or frequency of testing for STIs.
Did not increase social harm or other adverse events (only one case of social harm was reported and was not directly related to HIVST).
Uptake of HIV testing
HIVST increased the uptake of HTS. Three (35–37) of the five randomized controlled trials reported on uptake of HIV testing. A meta-analysis of these results indicated that HIVST doubled the uptake of HIV testing compared to standard HTS (Relative Risk (RR) = 2.12; 95% CI: 1.51, 2.98) (see ). (See Annex 16 for further details.)
Meta-analysis of HIV testing uptake at three and six months. M-H: Mantel-Haenszel; CI: Confidence interval.
The two studies, in Kenya where women distributed HIVST kits to their male partners, also reported an increased uptake of couples testing when compared with the approach of giving male partners letters or vouchers inviting them to test at a clinic (35,36).
Among men who have sex with men in Hong Kong SAR, one study (37) reported that uptake of HIV testing was higher in the HIVST group compared to the facility-based HIV testing group, both in the sub-groups of recent testers (>1–3 tests in 3 years) (RR = 1.75; 95% CI: 1.46, 2.08) and non-recent testers (0 tests in 3 years) (RR = 2.22; 95% CI: 1.61; 3.08). Analysis of uptake in this study also showed that the men who have sex with men who reported condomless anal intercourse at enrolment were also more likely to test if they were in the HIVST group compared to the standard HTS group (RR = 1.75; 95% CI: 1.26, 1.81) (37). These results suggests that higher risk men who have sex with men may be more likely to take up HIVST than standard facility-based HTS.
These findings are consistent with results from other systematic reviews (4,6,38), trials and observational studies from Kenya (39,40), Lesotho (41), Malawi (10,42) and Zimbabwe (16), which report similar increases in the uptake of HIV testing following the offer of HIVST. For instance, a two-year cluster randomized trial in Malawi reported uptake of directly assisted community-based HIVST among the general population at approximately 76.5% (crude uptake: 84%, 14 004/16 660) when adjusted to account for population turnover (10). Over the two-year period, the study reported that 44% were first-time testers. Uptake was consistently high in years one and two among adolescents (16–19 years of age) (95%; 2374/2502 and 2405/2502), young people (16–29 years of age) (90%; 8333/9315 and 8503/9315), women (85%; 6835/7802 and 6445/7802) and men (68%; 5902/8643 and 5924/8643) (10). Likewise, studies among key populations, primarily men who have sex with men and female sex workers, also report high uptake of HIV testing when HIVST is offered (4,5).
Frequency of HIV testing
HIVST increased the frequency of HIV testing among men who have sex with men. Two of the five randomized controlled trials reported on frequency of HIV testing among men who have sex with men (33,34). Across both studies, men in the HIVST group had a mean of two more tests in a 12–15 month period than those in the facility-based HTS group (mean difference = 2.13; 95% CI: 1.59, 2.66) (33,34) (see ).
Meta-analysis of mean number of tests among men who have sex with men in 12–15 month period. M-H: Mantel-Haenszel; SD: Standard deviation; CI: Confidence interval; IV: Independent variable.
In Australia, among non-recent testers (0 tests in >2 years or never tested) HIVST substantially increased the frequency of HIV testing compared to standard testing (33,34). The rate ratio for this sub-group showed that men in the HIVST group had a testing rate 5.54 times higher in a 12-month period than men in the standard HIV testing group (Rate Ratio = 5.54; 95% CI: 3.15, 9.74).
In the United States, HIVST was also shown to increase the uptake of quarterly HIV testing among men who have sex with men (76%; 74/98) compared to those receiving standard HTS (54%; 53/99) (33).
Although the results considered above are from a small number of studies, the reported increases in the frequency of HIV testing could have important public health implications, particularly when reaching people with undiagnosed HIV infections and those at high ongoing risk who are not accessing existing services. Sustained increases in frequency of HIV testing among higher risk populations of this magnitude or more, facilitated by HIVST, could identify a greater number of infections and result in a reduction in HIV incidence if individuals are effectively linked to prevention and treatment services (43,44).
HIV risk behaviour following HIVST
There was no increase in HIV risk behaviour identified following HIVST. One of the five randomized controlled trials reported on risk behaviour following HIVST (33). In this study, men who have sex with men in the HIVST group did not increase condomless anal intercourse compared to those receiving standard HTS, as reported at a nine-month follow-up (RR = 0.94: 95% CI: 0.55, 1.61). In this same study, men in the HIVST group acquired fewer bacterial sexually transmitted infections (STIs) than those in the standard HIV testing group (RR = 0.41; 95% CI: 0.15, 1.13).
Additionally, in Australia, HIVST was found to neither decrease nor increase the frequency with which men who have sex with men tested for STIs (34).
Although not reported in the reviewed randomized controlled trials, other observational studies suggest some users may be interested in using HIVST to screen potential sex partners (11,18,45,46). Studies have shown this could prevent users with a reactive self-test result from engaging in condomless sex (18,45). This evidence also suggests HIVST could be used to serosort (select a sex partner based on their self-reported HIV status) and to inform decisions about behaviour, including on using HIV prevention, such as condoms (18,45). In many of these studies, however, users were unaware that current HIVST technologies have a three-month window period and do not identify acute or early HIV infection.
While the decision to not use condoms may be appropriate in longer term relationships, where both partners have low ongoing risk, serosorting following HIVST is not recommended in population groups with high HIV incidence (for example, sex workers and men who have sex with men) (47). Clear messages about the potential risks of using HIVST to make decisions about risk behaviour and use of HIV prevention need to be communicated, particularly to key populations who may be at high ongoing risk of HIV.
Social harm
Only one instance of harm, which was not directly related to HIVST, was identified in the review (35). In that randomized controlled trial, there was one report of intimate partner violence (IPV) in both the HIVST group and the standard HIV testing group (1/297 in the HIVST group; 1/303 in the control group) (35). In the HIVST group, the harm was not directly related to HIVST: the female participant reported that the occurred because she took part in the study without consulting her husband (35). The participant reported leaving home for approximately three weeks, before returning. At a two-month follow-up visit, she informed researchers that she and her husband had reconciled. In the standard HIV testing group, one female participant also reported IPV (35).
These results suggest that HIVST may not directly influence the risk of IPV, but that these risks largely depend on the setting, context and relationship dynamics of couples and partners. Such findings are consistent with those reported by systematic reviews assessing harm across all forms of HTS (48), couples HTS (49), and self-testing for HIV and other conditions and diseases (50), as well as other observational studies. In an urban setting in Malawi, results from a two-year cluster randomized trial reported no cases of IPV, self-harm or suicide resulting from HIVST or other HIV testing in the community (10). In the United States, a study reported that, out of 124 events where men offered HIVST to their male sexual partners, 7 resulted in a verbal confrontation and none resulted in physical violence (45).Several studies have also shown that some initial reports of “coercion” to test were rather “persuasion” or “encouragement” to test (10,20,51). For example, in Malawi, it was primarily men who self-tested with their female partner who reported being coerced to test; of whom 94.4% (252/267) also said they would recommend HIVST to friends and family, and 92.2% (130/141) said they were highly satisfied with HIVST (10).
Nevertheless, while most users consider HIVST to be empowering (20,51), a study in Malawi on couples who received HIVST kits reported that two of 17 couples felt pressured by their partner to self-test and found dealing with serodiscordant results challenging (20). Likewise, in Kenya, four of 265 HIV-negative pregnant and postpartum women and female sex workers who distributed HIVST kits to their male partners and clients reported instances of IPV; two were among postpartum women and two were among female sex workers (18). It was unclear if these cases were directly linked to HIVST since prior to the intervention 41% of all female study participants said they had experienced IPV in the preceding 12 months. The two women in postpartum care who reported experiencing verbal abuse in a confrontation with their husbands said this was regarding a reactive test result (18). Both women left their homes but later returned and reconciled with their husbands. One woman reported that her husband (who was diagnosed HIV-positive) has since enrolled in care and that they are now using condoms during sex (18). Of concern are the two cases among female sex workers who distributed HIVST to their clients and experienced physical violence; one reported forced condomless sex (18), suggesting that not all testing approaches are appropriate for all contexts, and that caution may still be needed among vulnerable populations.
While the overall results are encouraging, it is critical for programmes to recognize the importance and complexity of monitoring, reporting, evaluating and assessing social harm in relation to HIVST. As recommended with all HTS, programmes need to consider context-specific approaches to implementing HIVST in ways that are ethical, safe and acceptable. In addition, risk mitigation in relation to social harm and the establishment of active monitoring and reporting systems are important.
HIVST positivity
A major aim of any HTS approach is to be as efficient and effective as possible in reaching people with undiagnosed HIV. One of the five randomized controlled trials reported on HIV positivity (33), and indicated that men who have sex with men in the HIVST group were twice as likely to have an HIV-positive test than those in the standard care group (RR = 1.97; 95% CI: 0.37, 10.52).
No other randomized controlled trials included in the GRADE analysis reported on HIV positivity, that is, the proportion of people with a reactive and confirmed positive HIV self-test result. However, several other studies on HIVST, which do not make a direct comparison with standard HTS, report HIV positivity ranging from 3–14% among the general population in sub-Saharan Africa and from 1–30% among key populations (see ).
Summary of HIV positivity studies implementing HIVST.
Despite the lack of a comparison with standard HTS, these studies describe HIV positivity on a par with that reported in many other HTS approaches in similar populations and settings (38).
It is important to note that, as HTS coverage increases, the proportion of HIV-positive tests and new diagnoses will likely decrease across all approaches. Thus, more strategic and focused methods will be required in order to continue to achieve similar, or greater, levels of HIV positivity for all HTS approaches, including HIVST.
2.2.3. Values and preferences on HIVST
In the process of identifying studies for the GRADE analysis, 125 studies which reported on some aspect of values and preferences and feasibility in relation to HIVST among actual or potential self-testers, health workers, policy-makers or other key stakeholders were identified. Study locations were: across the Americas – Brazil (63–66), Canada (67–69), Mexico (70), Peru (9,71), Puerto Rico (72), the United States (12,45,58,61,73–104); Africa – Ethiopia (22), Kenya (14,18,23,39,40,105–112), Lesotho (41), Malawi (10,19,20,42,51,113,114), Nigeria (115), South Africa (116–121), Zambia (15,122,123), Zimbabwe (16,52,56,124,125); Asia and the Pacific – Australia (8,29,126–130), China (24,53,54,62,131–140), India (17,141), Singapore (142), Viet Nam (55); Europe – France (143–145), Italy (146), the Netherlands (147–149), Spain (150–153), the United Kingdom (11,154); and other multi-country studies (21,46,155–158). One of the randomized controlled trials also reported on values and preferences on HIVST among men who have sex with men in Australia (34). Several systematic reviews also assessed values and preferences in relation to HIVST (4–7), including a qualitative synthesis (159).
In addition, a qualitative values and preferences study among fishing communities, sex workers, general populations and health workers in Uganda, and young key populations in Indonesia, Pakistan, Philippines and Thailand, was conducted to inform these guidelines (160,161).
An overview of the results of these studies are presented here according to key population, general population, couples and partners, young people (15–24 years of age), and health workers and other key stakeholders.
Key populations
Acceptability and willingness to use HIVST is generally high among key populations (4,18,56,112,131,132) despite some reported concerns about the potential lack of support, possible social harm, the level of accuracy of test results, and the related costs which could hinder access (4,72,80). Overall, the benefits of HIVST most commonly cited by key populations were convenience and privacy, followed by HIVST being an easy and painless testing option (4,80) as well as not needing a facility visit (112).
Some studies among men who have sex with men and female sex workers reported preferences for oral fluid-based RDTs for HIVST because this is a painless testing option. In contrast, other users said they preferred fingerstick/whole blood-based RDTs for HIVST as they considered them to be more accurate (11,55). For example, a study in Viet Nam reported that people who inject drugs preferred HIVST using a fingerstick/whole blood-based RDT, whereas more men who have sex with men and female sex workers said they favoured oral fluid-based RDTs (55).
Although there are many possible ways and channels for distributing HIVST, some studies suggest that men who have sex with men, transgender women and female sex workers prefer HIVST to be available over-the-counter at pharmacies and other locations or through the Internet (4). Several studies in Australia, China, Brazil, Peru, the United Kingdom and the United States reported that a high proportion of men who have sex with men and transgender women were comfortable accessing HIVST through the Internet and online gay dating sites, which mail a kit to their home or a location of their choice (4,9,57,66,100,154). Other options, such as vending machines and distribution at events, have also been shown to be acceptable among men who have sex with men and transgender people (98,99,101). In Kenya, female sex workers reported preferences for accessing HIVST kits at pharmacies or private clinics rather than obtaining them at public sector clinics (112), as well as a willingness to distribute HIVST to their peers, social network, primary partners and clients (18).
Case example: “A hora é agora” (“The time is now”): an internet-based HIV self-testing strategy in Brazil
“A hora é agora” (“The time is now”), is a comprehensive programme to increase HIV testing and linkage to care among men who have sex with men in the city of Curitiba, Brazil. The programme uses a secure web-based platform (www. ahoraeagora.org/) and both iOS and Android apps to offer men who have sex with men free oral-fluid HIV self-testing (HIVST) (up to two kits every six- months), as well as condoms and lubricants, and support to promote linkage to care.
Men can access video tutorials and multimedia instructions on how to correctly use the HIVST kit and interpret the results; they can receive additional support through a 24/7 telephone hotline. Individuals with a reactive or inconclusive self-test result are instructed to seek confirmatory testing at Curitiba's HIV counselling and testing centre (COA), where those with a reactive self-test are given confirmatory testing and if confirmed HIV-positive then supported to link to treatment and care. This programme is actively promoted using virtual and mobile media (social networking, dating websites), as well as face-to-face peer interventions at social/sexual gatherings.
As of 31 January 2016, the programme distributed over 4,000 HIVST kits, the majority of which were sent by mail. 17% (432/2527) of men who have sex with men who requested a HIVST kit self-reported their test results through the web-based platform. Out of these, 4% (19/432) reported having a reactive self-test result. Overall, 81% (30/37) of men who have sex with men who reported self-testing and received confirmatory testing at the COA were confirmed HIV-positive.
Source: Annex 3.
General populations
In the studies considered, HIVST was viewed to be highly acceptable by the general adult population, where there was strong support to promote and use HIVST.
In many African countries, interest in HIVST was consistently high. In Zimbabwe, a cross-sectional study among 289 adults found 80% would self-test, and nearly 90% would self-test if the cost was low (124). Likewise, in Zambia, 76% (1216/1600) said if HIVST were available they would definitely use it (122). In Kenya, a synthesis of several studies reported that privacy and personal empowerment were key motivations to self-test for HIV and that users would like to access HIVST kits at clinics or pharmacies (111). In-depth qualitative interviews in South Africa also indicated high acceptability of HIVST, as it was perceived to be a way to overcome barriers to existing HTS, such as lack of trust in health workers and the health system (117).
In Europe and the region of the Americas, similar levels of high acceptability were identified among general populations (76,150,153,154). In the United States, in 2006, prior to the availability of HIVST, 56.2% (95% CI: 54.7, 57.7) of adults who participated in a telephone survey indicated HIVST as acceptable (76), and two thirds of at-risk populations expressed a desire to use HIVST (76). In Spain, 80% (2699/3373) of individuals attending a street-based HTS site were in favour of making HIVST available (153). Additionally, 84% (174/207) of those accessing unassisted HIVST using fingerstick/whole blood-based RDTs in Spain said they were motivated to self-test for HIV in the future (150). In the United Kingdom, among 555 users who self-tested using a fingerstick/whole blood-based RDT, 98% said they would use it again and reported it was easy to perform (154).
Potential barriers to HIVST among the general population included concerns about the risk of violence, self-harm or suicide; misuse of HIVST kits; accuracy; lack of support; and potentially high costs. For example, in Kenya, 61% (n=1133) of people said HIVST kits might be misused, and there were also concerns about suicide or non-disclosure of self-test results (110). In Zambia, similar concerns were reported, albeit on a smaller scale: although 35% (n=1617) of respondents said they had concerns about HIVST, 98% of them said these concerns were minor and could be addressed (122). Concerns about the accuracy of HIVST were generally in relation to how to perform the test correctly and whether fingerstick/whole blood-based RDTs or oral fluid-based RDTs were more accurate (122). In one qualitative study in South Africa, a proportion of male respondents indicated they would prefer HIVST using fingerstick/whole blood-based RDTs because they perceived them to be more accurate (117).
Although concerns were raised about social harm in several of the studies, it is important to note that nearly all of those studies were conducted among individuals who had never self-tested for HIV. In contrast, in the studies in which HIVST was implemented, reports of social harm were rare (see section 2.2.1). Furthermore, in the studies considered, despite the various concerns raised by users, there was a consistently high level of interest and desire for HIVST to be readily available.
Couples and partners
In the studies considered, couples and partners from the general population and key population groups in Kenya (14,18,40,105), Malawi (20,51) and the United States (45,58,92,94,95,102,162) reported a high level of acceptability and interest in using HIVST.
Men who have sex with men in the United States, particularly those with casual partners and who do not use condoms, reported that they were interested in using HIVST as a form of harm reduction by screening potential sex partners (45,92,95,102,162). In two related studies, high-risk men who have sex with men suggested HIVST could improve honesty in disclosure of HIV status (102) and reported that, after their partner had a reactive self-test result, they provided emotional support and linked their partner to care (92). Service providers also report that couples-based HIVST could be a health promotion approach for men who have sex with men (102,162).
Among heterosexual cohabiting couples, HIVST may be a preferred approach to both determine one's HIV status and strengthen a relationship. In Malawi, HIVST was seen as an enabling, innovative way to test with a partner, strengthen a relationship bond and address concerns about suspected infidelity (20,51). Among women, in Malawi, the motivation to self-test as a couple was reportedly driven by long-term goals of health and “togetherness”, while men reported that they needed persuasion to self-test (although this was perceived as beneficial) and viewed HIVST as more flexible and less intimidating than HTS at a facility (20). HIVST also provided a way for couples to disclose a previously concealed HIV-positive status, alleviating internal conflict (20). Studies in Malawi and Kenya also demonstrated that distribution of an HIVST kit to a partner was perceived to be both safe and acceptable (19,105).
In Kenya, HIVST was highly acceptable among serodiscordant couples who were aware of their partner's status and were using PrEP (40). According to a cross-sectional study among 120 couples, 92.5% of couples found HIVST easy to use and nearly 40% self-tested with their partner (40).
As with all HTS, it is important to consider the potential risks, as well as benefits, to couples and partners. While studies to date, and the evidence summarized above, indicate that there are many benefits and that the risk of harm is minimal, it remains true that coercion or IPV are possible, depending on the context, setting and relationship dynamics. Coping with serodiscordant results can be challenging, whichever way HIV testing is performed or delivered. Some partners who self-test together and have non-reactive test results may forgo condoms, which could lead to the acquisition of HIV or other STIs if they have additional sexual partners. However, other couples who self-test together and have a reactive or serodiscordant result could be more likely to use condoms and support each other in linking to further HIV testing and HIV prevention and treatment services – bringing multiple benefits, including the prevention of future HIV transmission. Like other forms of couples and partner HTS, HIVST may not be appropriate for individuals or couples who report IPV in their current relationship (49). Thus, clear messages and information need to be delivered to couples and partners to mitigate potential risks and maximize benefits. (See section 2.2.1 above and Chapter 4 for additional information, as well as section 5.4 in Chapter 5 of the Consolidated guidelines on HIV testing services.)
Young people (15–24 years of age)
Although the number of existing studies that look at young people's (15–24 years of age) willingness to use HIVST kits are few, they report considerable interest in accessing HIVST in Canada (68), France (143), South Africa (116) and the United States (12,80,103,104).
In Canada, a survey of university students reported that 81% thought unassisted HIVST using an oral fluid-based RDT was acceptable, despite some concerns about accuracy and linkage to care (68). Similar findings were identified among South African university students (116), who also suggested HIVST was empowering, could “normalize” HIV, and that subsidized or free test kits may help people access HIVST.
In the United States, three studies reported high willingness to use HIVST kits among high-risk young people (12,103,104). One of these studies suggested the key motivations to self-test for HIV were ease of access, no need for a clinic visit, quick results, and the fact that HIVST kits could be used in non-monogamous relationships (104). However, the study noted that young people lacked information about the window period (104). Another study among young African Americans also indicated HIVST as preferable to facility-based HTS because it provides privacy and increases convenience, whilst reducing stigma and normalizing HTS (12,103). However, young people expressed concerns about accessing confirmatory testing, coping with a reactive self-test result, and whether people with a low socio-economic status would be able to understand the instruction materials provided (12,103). Similar preferences were reported among young people in France, especially if HIVST were available free of charge or came with the option of having assistance (143).
Health workers and other key stakeholders
HIVST is highly acceptable to health workers in high HIV prevalence settings for testing themselves, particularly those who have never tested before. The rate of informal HIVST among health workers is high in Ethiopia, Kenya, Malawi, Mozambique and Zimbabwe (7), where health workers view HIVST as a way to reduce stigma and discrimination around HIV testing and as a way for their family members to test (7). In Ethiopia, 70% (n=307) of health workers reported they had self-tested for HIV informally (22). Of those who self-tested, 82% said they did so for greater confidentiality and 14% said they self-tested because they lacked the time to receive standard HTS (22). In Kenya, a feasibility study reported that, following distribution of HIVST kits and provision of an information session, 89% (680/765) of survey respondents said they would recommend HIVST to fellow health workers (14).
Health workers and key stakeholders who provide or support the delivery of HTS report HIVST to be highly acceptable when implemented appropriately, using accurate and easy-to-use RDTs, and when there is linkage to care (69,157,158). In two studies in Canada, key stakeholders and health workers said HIVST should be made available nationally (67,69). One of the studies in Canada showed that one third of providers wanted further education on HIVST and preferred a more community-based approach for distributing HIVST kits (67). In Zimbabwe, focus groups revealed that, while health workers perceived HIVST to be a way to reach people with undiagnosed HIV, particularly men and those living in areas where there is limited access to HTS, they had concerns about how HIVST could impact their jobs and the jobs of other health workers (125).
(See Annex 17 for the full GRADE systematic review, including values and preferences in relation to whether HIVST should be offered as an additional HTS approach.)
2.2.4. Cost and cost-effectiveness
The potential cost of implementing HIVST, or buying RDTs for self-testing, is a concern for both policy-makers and end users. Three studies (163–165) and one report (28) identified in the review process included information on cost and cost-effectiveness.
The UNITAID/WHO assessment of the market landscape estimated that in high-income settings HIV RDTs for self-testing are directly available to consumers for approximately US$ 7.50–43 and in low- and middle-income countries (in the context of research) for US$ 3–16 (28,31). Due to the cost of additional packaging and modifications to the test kit, as well as a number of market uncertainties, the prices for HIV RDTs for self-testing are currently higher than those for professional use (US$ 0.50–11 per test kit) (28).
When assessing the cost of HIVST, it is important to not only consider the unit price per test kit, but also the financial impact of different HIVST approaches in varying settings and among various populations.
In the United States, the distribution of unassisted HIVST through a gay dating application reported that total programme costs of distributing 455 kits were high (US$ 17 600), but that this was driven by the cost of the test kit (US$ 26). The cost of personnel and advertising made up only 25% of the total programme costs. Using a lower-cost test kit would make this unassisted HIVST approach substantially more cost-effective (163).
As illustrated by a costing study of assisted community-based HIVST in Malawi, where trained provider were available and supported self-testers as needed, the mean health provider cost per participant tested through community-based HIVST, at US$ 8.78, was comparable to the cost per participant of testing through facility-based HTS, at US$ 7.53–10.57 (165). When HIVST was considered on the basis of cost per HIV-positive case identified, community-based HIVST was associated with a higher mean health provider cost, at US$ 97.50, than facility-based HTS, at US$ 25.18–76.14 (165). These findings are reflective of lower HIV prevalence among those reached through community-based HIVST as well as an HIVST approach in which personnel and monitoring systems were more expensive and accounted for a greater proportion of total costs compared with facility-based HTS. These costs would likely be much lower if approaches were more focused and used methods that reduced the level of direct assistance, such as by giving group HIVST demonstrations or using social media or videos to provide instructions and support. Costs would also be lower if less expensive but effective monitoring and evaluation systems were utilized and if the unit price of HIVST kits decreased.
According to a mathematical model based on data from Zimbabwe, HIVST can be cost-effective if test kits cost US$ 3 per unit and there is a moderate (20%) increase in HIV testing due to HIVST (164). In this context, the community-based HIVST model would save US$ 75 million in health-care costs and avert approximately 7000 disability-adjusted life years over 20 years (164). Using available data, this mathematical model was updated to assess the cost-effectiveness of different HIVST approaches in Zimbabwe (community-based, partner-distributed and pharmacy-based). It was found that, given the high testing coverage and that approximately 85% of people with HIV know their status, the majority of all other additional HTS approaches would be less cost-effective than HIVST. HIVST, however, was shown to be cost-effective (considering a US$ 500 cost-effectiveness threshold) when it was utilized in secondary distribution to reach male partners, distributed through pharmacies and to female sex workers in the community (166).
It is likely that HIVST will be more cost-effective in settings with lower testing coverage if linkage to care following self-testing increases, and if HIV-negative individuals link to HIV prevention such as PrEP and VMMC, and if individuals at high ongoing risk of HIV increase their frequency of testing. As more countries move toward implementing ‘treat all’ policies, implementing HIVST will likely become more cost-effective since all persons diagnosed HIV-positive will be eligible for antiretroviral therapy (ART), which will result in additional health benefits. Further, while current HIVST kits are more costly than professional-use RDTs, many efforts are underway to develop new products and decrease prices.
2.2.5. Systematic review and meta-analysis on performance of HIV RDTs for self-testing
This section summarizes results of a systematic review on the performance of HIV RDTs used for self-testing. (See Annex 19 for more detailed information.)
To identify evidence on the performance of HIV RDTs for self-testing, reviewers searched three electronic databases and six conference databases, covering the period up to the end date of 1 April 2016. Additional gray literature was searched through Google Scholar. Studies were included if they were conducted among individuals who self-tested using an HIV RDT and reported on the concordance or the sensitivity and specificity of these RDTs compared to testing performed by a trained health worker.
From an initial screen of 2332 titles, 25 studies were included in the review, including two randomized controlled trials (167,168); the remainder were observational studies. The 25 studies were diverse in terms of design, but all reported on concordance between the result of an HIV RDT used by a self-tester compared to the result obtained by a trained health worker. The studies were primarily in urban settings (n=20), with only four in rural settings (17,167,169,170) and one reporting on both settings (168). Fifteen studies used oral fluid-based HIV RDTs only (10,17,42,68,96,108,131,167,168,170–175), six used fingerstick/whole blood-based RDTs only (142,150,169,176–178) and four used both oral and blood specimens (84,85,179,180). Eleven studies provided direct assistance to self-testers (10,17,42, 68,85,131,167,170,175,176,178), thirteen were unassisted (68,84,96,108,142,168,169,172–174,177,179,180), and one study provided both approaches (150).
Box 2.3Overview of study results on the performance of HIV RDTs for self-testing
In general, the studies reviewed concluded that:
An HIV
rapid diagnostic test (RDT) used and interpreted by a self-tester can perform as well as an HIV RDT used and interpreted by a trained health worker.
HIV RDTs used by self-testers can achieve acceptable
sensitivity and
specificity, especially when appropriate and quality products are utilized and when a demonstration or other support tools, such as instructions for use and videos, are provided.
Performance of HIV RDTs for self-testing
An HIV RDT used and interpreted by a self-tester performs as well as an HIV RDT used and interpreted by a trained health worker. Across 16 studies using directly assisted or unassisted HIVST, and one study reporting on both, kappa agreement between self-testers and trained health workers was almost perfect (see ). No differences in concordance between self-testers and trained health workers were identified by type of approach, observation, type of specimen or HIV positivity (directly assisted: 0.98, 95% CI: 0.96–0.99 vs. unassisted: 0.98, 95% CI: 0.96–0.99; I2 33%, 95% CI: 19.5–98.1).
Concordance of test results performed by self-tester compared to trained health worker (measured by Cohen's kappa) (n=16). Source: Figueroa et al, 2016 (181).
HIV RDTs used by self-testers can achieve high sensitivity and specificity. While there was a wide range in reported sensitivity, only two of 20 studies reported sensitivity of less than 80%; one of these studies did not provide sufficient information on how to interpret faint positive lines (175), and the other study suggested lengthy instructions were a barrier among participants in the rural arm, where literacy levels were low (52). Excluding these two studies with sensitivity less than 80%, sensitivity and specificity estimates were higher for fingerstick/whole blood-based RDTs (84,142,169,177) compared to oral fluid-based RDTs (10,17,42,108,131,167,168,170,171,173–175) (sensitivity 96.2–100% vs. 80–100%; specificity 99.5–100% vs. 95.1–100%). However, overall, there was no difference in sensitivity or specificity between approaches that offered direct assistance compared to those that did not (181) (see ).
Sensitivity and specificity of RDTs used for self-testing by type of approach (n=16).
Although sensitivity and specificity were typically high, common errors in performing the self-test or misinterpreting the self-test results were identified, such as errors in collecting the specimen (finger-prick or oral-swab) (42,131,168,178) and incorrect use or spilling of the buffer (42,168,170,171,174). Some of these errors resulted in invalid self-test results, such as errors in collecting the specimen, and others resulted in reduced test sensitivity. Studies using fingerstick/whole blood-based RDTs (84,85,150,169,178,180) reported a greater proportion of invalid results compared to studies using oral fluid-based RDTs (0.4–9.5% vs. 0.2–4.5%) (17,42,84,85,131,167,168,170,171,173,174,179,180).
In Zimbabwe, a study among a rural population with low literacy levels, which reported poor test sensitivity (66.7% 95% CI 9.4, 99.2), suggested user errors performing the self-test and interpreting the results were likely due to difficulties in reading and comprehending the instructions for use (168). Also, several studies that included people with known HIV-positive status reported that these users may have been more likely to make errors in performing a self-test or interpreting the self-test result (171,177).
HIV RDTs for self-testing among individuals on antiretroviral (ARV) drugs
Three of the 25 studies included in the review reported on whether or not participants were taking ARV drugs for treatment or prevention, including studies among participants with known HIV-positive status. These studies used an oral fluid-based RDT; in two of them, participants taking ARV drugs had a non-reactive self-test result and were later confirmed HIV-positive using a validated testing algorithm (10,168), whilst in the third study, both the HIVST and confirmatory test results were non-reactive because the reference standard was the same oral fluid-based RDT (179). While there is limited evidence on the impact of ARV drugs on the performance of HIV RDTs, several studies suggest they may be more likely to cause false non-reactive test results when using serology (antibody) tests because HIV antibodies are suppressed and remain undetected (2,182). This may be a risk for all serology tests, particularly oral fluid-based RDTs. (See Chapter 7 of the Consolidated guidelines on HIV testing services.) Therefore, it cannot be ruled out that studies reporting low sensitivity may have included populations taking ARV drugs.
Although HIVST can be highly accurate – as high as 100% sensitivity and 100% specificity, particularly with validated tests and instructions for use (181) – as with all HIV testing, a single reactive HIV RDT result is not sufficient to provide an HIV-positive diagnosis. All reactive self-test results must be confirmed by a trained tester starting from the beginning of a validated national testing algorithm (2). Currently, it is not recommended for individuals to attempt their own confirmatory testing through HIVST.
(For more detailed information on this systematic review on the performance of HIV RDTs for self-testing, please refer to Annex 19.)